At the news
? NEUTRALIMPACT 4/10 8-K filed Aug 5, 2026 at 17:17 ET
AbbVie entered into an underwriting agreement to issue and sell $10.0 billion aggregate principal amount of senior notes across nine tranches, with net proceeds of approximately $9.93 billion. The funds will partially finance the acquisition of Apogee Therapeutics and reduce commitments under a $10.0 billion delayed draw term loan facility. This is a routine debt capital markets transaction for a large investment-grade issuer, increasing leverage but securing financing for a strategic acquisition.
- AbbVie issued $10.0 billion aggregate principal amount of senior notes across nine tranches with maturities from 2028 to 2066.
- Net proceeds are expected to be approximately $9.93 billion.
- Proceeds will fund a portion of the cash payment obligations for the acquisition of Apogee Therapeutics, Inc. and for general corporate purposes.
- The issuance will reduce commitments under AbbVie's $10.0 billion 364-day delayed draw term loan facility entered into in connection with the Apogee acquisition.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access